The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.
Teva is planning to up its stake in Mylan prior to a possible legal challenge; Perrigo acquires GSK OTC portfolio; Express Scripts considers creative ways to drive down drug costs
Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill
While the FDA is not required to follow the panel's recommendation, the agency's final decision on Orkambi is crucial to Vertex's future.
Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways
A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.
UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals
Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
In a bid to compete with CVS Caremark, pharmacy retailer Rite Aid has purchased pharmacy- benefit manager Envision Pharmaceutical Services.
- Insurance trade group says new HCV drugs could cost California billions
- FDA advisory panelists describe decision to recommend approval of "female Viagra"
- Five things for pharma marketers to know: Tuesday, July 7
- Curious if you're a finalist in the MM&M Awards? Find out now
- Vertex's Orkambi nabs FDA approval but may face payer backlash